Gyre Therapeutics, INC 8-K filings

Gyre Therapeutics announced its second quarter 2026 financial results, reporting $29.1 million in revenue and affirming full-year revenue guidance, while also detailing progress on its pipeline and the acquisition of Cullgen.

Gyre Therapeutics announced the appointment of three new directors to its Board, effective August 1, 2026, to enhance scientific, clinical, and operational expertise.

Gyre Therapeutics, Inc. has filed an amendment to its Form 8-K to include financial statements of Cullgen Inc. following their merger on May 4, 2026.

Gyre Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and key proposals were approved.

Gyre Therapeutics, Inc. has released an updated corporate presentation detailing its integrated biopharmaceutical strategy, pipeline advancements, and operational efficiencies.

Gyre Therapeutics showcased preclinical data for its CDK2-cyclin E degrader, CG923308, targeting solid tumors and drug-resistant breast cancer.

Gyre Therapeutics announces China's NMPA has accepted the New Drug Application for F351 (hydronidone) for treating chronic hepatitis B-induced liver fibrosis.

Gyre Therapeutics has finalized its acquisition of Cullgen Inc. in an all-stock deal valued at approximately $300 million, creating a combined biopharmaceutical entity with U.S. and China operations.

Gyre Therapeutics filed an amendment to its merger agreement with Cullgen Inc., clarifying the stock conversion terms for non-designated holders in the $300 million all-stock transaction.

Gyre Therapeutics' subsidiary submitted a New Drug Application for its lead candidate F351 (Hydronidone) in China for chronic hepatitis B-induced liver fibrosis.

Gyre Therapeutics presented optimistic projections for future revenues from key products and highlighted advancements in its R&D pipeline at an investor conference.

Gyre Therapeutics will acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million, creating a fully integrated biopharmaceutical company.

Gyre Therapeutics' subsidiary, Gyre Pharmaceuticals, achieved CDE alignment for a conditional approval pathway and priority review eligibility for its anti-fibrotic therapy, Hydronidone, in China.

Gyre Therapeutics reports strong third-quarter profit growth but revises full-year revenue guidance downward due to product rollout delays and market uncertainties.

Gyre Therapeutics announced positive Phase 3 clinical trial results for Hydronidone in treating CHB-related liver fibrosis, paving the way for regulatory filings.

Gyre Therapeutics announced the appointment of Dr. Dan Weng, a seasoned biopharmaceutical executive with extensive global clinical trial and regulatory experience, to its Board of Directors.

Gyre Therapeutics reported Q2 2025 financial results, including $1.6 million net income, reaffirmed full-year revenue guidance, and appointed Ping Zhang as interim CEO.

Gyre Therapeutics, Inc. announced that all director nominees were elected and all proposals, including executive compensation and auditor ratification, were approved by stockholders at its 2025 Annual Meeting.

Gyre Therapeutics, Inc. has announced the pricing of a public offering of 2,222,222 shares of its common stock at $9.00 per share, expecting to raise approximately $18.5 million in net proceeds to advance its Phase 2 clinical trial for F351 in MASH-associated liver fibrosis.

Gyre Therapeutics announces its lead compound, Hydronidone, met the primary endpoint in a pivotal Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B in China.

Gyre Therapeutics announces Q1 2025 financial results with a net income of $3.7 million and reaffirms its full-year revenue guidance of $118-$128 million.

Gyre Therapeutics provides an update on its corporate strategy and pipeline development, focusing on the potential of F351 (Hydronidone) as a first-in-class therapy for CHB-related and MASH-related liver fibrosis.

Gyre Therapeutics reports its Q4 and full year 2024 financial results, highlighting upcoming milestones including Phase 3 trial data and commercial launches, with a revenue guidance of $118 to $128 million for 2025.

GNI Group Ltd. announces its FY2024 consolidated financial results, highlighting a revenue decrease but progress in pharmaceutical development and strategic initiatives.

Gyre Therapeutics has announced the resignation of its Chairman, Ying Luo, and the appointment of Ping Zhang as a new director and lead independent director, effective January 5, 2025.

Gyre Therapeutics has entered into an agreement to sell up to $50 million of its common stock through an at-the-market offering.

Gyre Therapeutics reported its third quarter 2024 financial results, highlighted by $25.5 million in revenue and progress in clinical trials, with several key milestones expected in 2025.

Gyre Therapeutics reported its second quarter 2024 financial results, highlighted by $25.2 million in revenue and progress in clinical development and commercial expansion.

Gyre Therapeutics has appointed David Epstein, Ph.D., a seasoned biotech executive, to its Board of Directors, effective August 6, 2024.

Gyre Therapeutics is out of compliance with Nasdaq's audit committee requirements following a board member's resignation, triggering a cure period to find a replacement.